Ranjan Pai is among India’s most influential investors. So, when he makes a move into senior care, it is time to sit up and take notice of the sector, not to mention the broader grey economy.
Related Posts
usfda: Closer USFDA lens will keep Indian pharma edgy, but companies now better placed to handle the glare
Three months ago, Robert M Califf, commissioner of the US Food and Drug Administration (USFDA) visited India to strengthen efforts…
Lifesaver to litigant: how a Covid-19 drug drove a wedge between Max Healthcare and Novacare
Synopsis Ronapreve came as a boon at the peak of the Delta wave in 2021. But as the injection turned…
High risk of adverse reaction to two diabetes drugs: Doctors advise caution; will patients be safe?
Canadian physician William Osler is said to have once remarked that medicine is a science of uncertainty and an art…
